ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

PRQR ProQR Therapeutics NV

1.99
-0.01 (-0.50%)
After Hours
Last Updated: 22:59:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
ProQR Therapeutics NV NASDAQ:PRQR NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.01 -0.50% 1.99 1.92 2.08 2.05 1.97 2.01 30,250 22:59:00

Report of Foreign Issuer (6-k)

28/02/2017 12:45pm

Edgar (US Regulatory)


 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

February 28, 2017

PROQR THERAPEUTICS N.V.

Zernikedreef 9

2333 CK Leiden

The Netherlands

Tel: +31 88 166 7000

(Address, Including ZIP Code, and Telephone Number,

Including Area Code, of Registrant’s Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒  Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

Attached as Exhibit 99.1 to this Report on Form 6-K are the unaudited financial statements of ProQR Therapeutics N.V. (the “Company”) for the three months and year ended December 31, 2016 and attached as Exhibit 99.2 to this Report on Form 6-K is a press release of ProQR Therapeutics N.V. dated February 28, 2017, announcing the Company’s results for the three months and year ended December 31, 2016.

The Company hereby incorporates by reference the information contained herein into the Company’s registration statement on Form F-3 (File No. 333-207245).

 

 

 

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

   PROQR THERAPEUTICS N.V.
Date: February 28, 2016    By:  

/s/ Smital Shah

     Smital Shah
     Chief Financial Officer


INDEX TO EXHIBITS

 

Number    

  

Description

99.1    Unaudited financial statements of ProQR Therapeutics N.V. for the three months and year ended December 31, 2016.
99.2    Press Release of ProQR Therapeutics N.V. dated February 28, 2017, announcing the Company’s results for the three months and year ended December 31, 2016.

1 Year ProQR Therapeutics NV Chart

1 Year ProQR Therapeutics NV Chart

1 Month ProQR Therapeutics NV Chart

1 Month ProQR Therapeutics NV Chart

Your Recent History

Delayed Upgrade Clock